Hill-Rom Holdings Inc. (NYSE:HRC) – Stock analysts at Northcoast Research lowered their Q1 2017 earnings estimates for Hill-Rom Holdings in a research report issued on Monday. Northcoast Research analyst D. Keiser now forecasts that the firm will post earnings per share of $0.76 for the quarter, down from their previous forecast of $0.78. Northcoast Research also issued estimates for Hill-Rom Holdings’ Q4 2017 earnings at $1.31 EPS and Q4 2018 earnings at $1.44 EPS.

Separately, Zacks Investment Research lowered shares of Hill-Rom Holdings from a “buy” rating to a “hold” rating in a research note on Wednesday. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Hill-Rom Holdings presently has an average rating of “Buy” and an average price target of $62.20.

Earnings History and Estimates for Hill-Rom Holdings (NYSE:HRC)

Shares of Hill-Rom Holdings (NYSE:HRC) opened at 53.16 on Thursday. Hill-Rom Holdings has a 12-month low of $42.99 and a 12-month high of $63.12. The stock has a market cap of $3.55 billion, a PE ratio of 28.58 and a beta of 1.20. The stock’s 50 day moving average is $58.84 and its 200-day moving average is $54.46.

Hill-Rom Holdings (NYSE:HRC) last posted its quarterly earnings results on Thursday, November 3rd. The medical technology company reported $1.18 EPS for the quarter, beating the Zacks’ consensus estimate of $1.13 by $0.05. Hill-Rom Holdings had a net margin of 4.67% and a return on equity of 18.93%. The firm had revenue of $706 million for the quarter, compared to analysts’ expectations of $701.39 million. During the same quarter in the prior year, the company posted $0.89 earnings per share. The business’s revenue for the quarter was up 23.0% on a year-over-year basis.

Several hedge funds have recently added to or reduced their stakes in the stock. BlackRock Group LTD increased its stake in Hill-Rom Holdings by 46.4% in the first quarter. BlackRock Group LTD now owns 62,884 shares of the medical technology company’s stock valued at $3,163,000 after buying an additional 19,939 shares during the period. Goldman Sachs Group Inc. increased its stake in Hill-Rom Holdings by 51.8% in the first quarter. Goldman Sachs Group Inc. now owns 337,464 shares of the medical technology company’s stock valued at $16,975,000 after buying an additional 115,170 shares during the period. Geode Capital Management LLC increased its stake in Hill-Rom Holdings by 3.4% in the first quarter. Geode Capital Management LLC now owns 357,514 shares of the medical technology company’s stock valued at $17,982,000 after buying an additional 11,790 shares during the period. Clark Capital Management Group Inc. increased its stake in Hill-Rom Holdings by 36.9% in the first quarter. Clark Capital Management Group Inc. now owns 20,637 shares of the medical technology company’s stock valued at $1,038,000 after buying an additional 5,560 shares during the period. Finally, Metropolitan Life Insurance Co. NY increased its stake in Hill-Rom Holdings by 3.0% in the first quarter. Metropolitan Life Insurance Co. NY now owns 53,881 shares of the medical technology company’s stock valued at $2,710,000 after buying an additional 1,565 shares during the period. 83.10% of the stock is currently owned by institutional investors and hedge funds.

About Hill-Rom Holdings

Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.

5 Day Chart for NYSE:HRC

Receive News & Stock Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related stocks with our FREE daily email newsletter.